Product name:Fulvestrant
Alias:Faslodex AstraZeneca
CAS Registry Number:129453-61-8
Assay: 97.0%~103.0%
Molecular Fomular:C32H47F5O3S
Molecular Weight:606.77
Density:1.201 g/cm3
Melting Point:104-106℃
Appearance:white powder
Grade : Pharmaceutical Grade
Storage: Shading, confined preservation
Other drugs in same class:Anastrozole,Letrozole,Tamoxifen citrate,Exemestane
Usage:Fulvestrant is a type of hormone treatment. It is also called Faslodex. It is a treatment for post menopausal women with advanced breast cancer. A novel steroidal estrogen antagonist reported to lack any partial agonist activity. Also used as an antineoplastic raw materials.
Description
| Product name | Fulvestrant |
| Other name | Faslodex AstraZeneca |
| CAS register number | 129453-61-8 |
| Molecular formula | C32H47F5O3S |
| Molecular weight | 606.77 |
| Molecular structure |  |
| Assay | 97.0%~103.0% |
| Appearance | White powder |
| Package | 1kg/aluminium foil bag or as required |
| Usage | can be used as pharmaceutical material |
| Minimum order quantity | 10g |
| Shipping | By express courier |
| Shipping leading time | Within 12 hours after receiving the payment |
| Payment options | , MoneyGram, T/T |
| Price | Negotiated |
Application
Fulvestrant (Faslodex, AstraZeneca) is a drug treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works by down-regulating the estrogen receptor.
Fulvestrant is a selective estrogen receptor down-regulator (SERD). Fulvestrant is indicated for the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy. The dosing schedule for fulvestrant remains under investigation in an attempt to optimize its effectiveness.
Fulvestrant provided effective second-line therapy in this setting for postmenopausal women who had relapsed or progressed after previous endocrine therapy.
In particular 4 clinical trials in this setting did show similar efficacy to the other hormonal agents (aromatase inhibitors and tamoxifen) with good tolerability profile. Fulvestrant had a lower incidence of joint disorders.
Many breast cancers are stimulated to grow by the female sex hormones oestrogen and progesterone. These breast cancers are called hormone sensitive or hormone receptor positive. Drugs that block the effects of these hormones can slow or stop the growth of the breast cancer cells. Fulvestrant stops oestrogen getting to the cancer cells by blocking oestrogen receptors and reducing the number of receptors the cancer cell has.
Specification
| TEST ITEMS | SPECIFICATION | RESULTS |
| Appearance | White to off-white powder | White to off-white powder |
| Identification | IR/HPLC | Conforms |
| Specific Rotation | +108°to +115° | +110.9° |
| Water | Not More Than 0.5% | 0.3% |
| Sulphated Ash | Not More Than 0.1% | <0.1% |
| Heavy Metals | Not More Than 20ppm | <10ppm |
| Single impurity | Not More Than 0.5% | 0.15% |
| Total impurities | Not More Than 1.0% | 0.45% |
| FulvestrantA | 42% ～48% | 45% |
| Fulvestrant B | 52% ～58% | 55% |
| Assay(on anhydrous basis) | 97.0% to 102.0% | 98.9% |
| Toluene | Not More Than 890ppm | 200ppm |
| Ethyl acetate | Not More Than 5000ppm | 1300ppm |
| Conclusion | The specification conform with enterprise standard. | |
Our products are sold all over the world, you can rest assured.
